Abstract IA39: Squamous cell lung cancer 2014.

Abstract

Abstract Despite the robust progress in developing molecularly targeted therapies for patients with lung adenocarcinoma, patients with other types of lung cancer have not benefitted much to date from molecularly targeted therapy. While in the past this was due to a lack of knowledge of the molecular underpinnings of other lung cancer types, large-scale genomic surveys have now demonstrated that relevant and targetable genomic alterations can be found in all histologies of lung cancer. Here I discuss recent data from genomic analyses of squamous cell lung cancer, the second most common type of non-small cell lung cancer and describe potential therapeutic targets in this disease with an emphasis on Fibroblast Growth Factor Receptors. I will summarize preclinical and early clinical studies and discuss how further progress in targeted therapy for squamous cell carcinomas can be made. Citation Format: Peter S. Hammerman. Squamous cell lung cancer 2014. [abstract]. In: Proceedings of the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer; 2014 Jan 6-9; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2014;20(2Suppl):Abstract nr IA39.